Population balance modeling of aggregation kinetics of recombinant human interleukin-1 receptor antagonist

被引:19
作者
Chi, EY
Kendrick, BS
Carpenter, JF
Randolph, TW [1 ]
机构
[1] Univ Colorado, Ctr Pharmaceut Biotechnol, Dept Chem & Biol Engn, Boulder, CO 80309 USA
[2] Amgen Inc, Longmont, CO 80503 USA
[3] Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci,Ctr Pharmaceut Biotechnol, Denver, CO 80262 USA
基金
美国国家科学基金会;
关键词
protein aggregation kinetics; precipitation; aggregate size distribution; excipients; preservatives; benzyl alcohol; formulation; nucleation rate; growth rate;
D O I
10.1002/jps.20488
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The kinetics of benzyl alcohol-induced normative aggregation of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) were investigated using a population balance model. Steady-state size distributions of rhIL-1ra aggregates formed in a continuous mixed suspension, mixed product removal (MSMPR) reactor were measured and used to extrapolate aggregate nucleation and growth rates parameters. Aggregate growth rate was size-dependent and a linear growth rate model was used to derive a population density function. Addition of 0.9 wt/v% benzyl alcohol increased the nucleation rate by approximately four orders of magnitude. The growth rate for aggregates, however, changed little as a function of benzyl alcohol concentration in the range of 0-0.9%. The addition of sucrose to buffer containing 0.9% benzyl alcohol decreased rhIL1-ra nucleation rate by orders of magnitude and had little impact on growth rate kinetics. The simplicity of the population balance model and the physical relevance of the information obtained from this model render it a useful tool to study protein aggregation kinetics and the effects of excipients on this process. (c) 2005 Wiley-Liss, Inc. and the American Pharmacists Association.
引用
收藏
页码:2735 / 2748
页数:14
相关论文
共 35 条
  • [1] CRYSTAL SIZE DISTRIBUTIONS IN CONTINUOUS CRYSTALLIZERS WHEN GROWTH RATE IS SIZE DEPENDENT
    ABEGG, CF
    STEVENS, JD
    LARSON, MA
    [J]. AICHE JOURNAL, 1968, 14 (01) : 118 - &
  • [2] Akers M. J., 1984, PHARM TECHNOL, V8, P36
  • [3] Excipient-drug interactions in parenteral formulations
    Akers, MJ
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (11) : 2283 - 2300
  • [4] AKERS MJ, 2001, P 2001 IBC C PROT FO
  • [5] SOME ASPECTS OF CRYSTALLIZATION THEORY - SYSTEMS THAT VIOLATE MCCABES DELTA L LAW
    CANNING, TF
    RANDOLPH, AD
    [J]. AICHE JOURNAL, 1967, 13 (01) : 5 - &
  • [6] Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation
    Chi, EY
    Krishnan, S
    Randolph, TW
    Carpenter, JF
    [J]. PHARMACEUTICAL RESEARCH, 2003, 20 (09) : 1325 - 1336
  • [7] Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor
    Chi, EY
    Krishnan, S
    Kendrick, BS
    Chang, BS
    Carpenter, JF
    Randolph, TW
    [J]. PROTEIN SCIENCE, 2003, 12 (05) : 903 - 913
  • [8] CLELAND JL, 1993, CRIT REV THER DRUG, V10, P307
  • [9] Debenedetti P. G., 1996, METASTABLE LIQUIDS C
  • [10] Spectroscopic study of secondary structure and thermal denaturation of recombinant human factor XIII in aqueous solution
    Dong, AC
    Kendrick, B
    Kreilgard, L
    Matsuura, J
    Manning, MC
    Carpenter, JF
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1997, 347 (02) : 213 - 220